Company intelligence / Profile preview

Carmot Therapeutics

Berkeley, California, United Statescarmot.us ↗

Ownership: Private
Employees: ~70
Development stage: Phase 2

Overview

Carmot has three clinical candidates targeting metabolic diseases. CT‑388 demonstrated substantial weight loss in a Phase 1b trial. CT‑868 is in a Phase 2 trial for overweight/obesity with T1D. CT‑996 is an oral small molecule GLP‑1 agonist in Phase 1 for obesity and T2D. All programs are designed to improve glycemic control and induce significant weight loss with good tolerability.

Therapeutic areas: Endocrinology
Modalities: small moleculespeptide therapeutics (notably GLP-1 and GIP receptor agonists)
Industry: Biotech

Drug pipeline

3 assets

CT-868

Phase 2

Indications: Obesity, Type 1 diabetes

2 more assets in the full pipeline.

Beyond the preview

Go deeper on Carmot Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carmot Therapeutics.